CHRS
Coherus Oncology, Inc.
Biotechnology
Market Cap$213M
5Y Perf.-90.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CHRS vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.61B
5Y Perf.-78.6%
CHRS vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CHRS | PRGO |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $213M | $1.61B |
| Revenue (TTM) | $42M | $4.18B |
| Net Income (TTM) | $168M | $-1.82B |
| Gross Margin | -37.3% | 34.2% |
| Operating Margin | -429.5% | -4.1% |
| Forward P/E | 1.2x | 5.6x |
| Total Debt | $1M | $3.97B |
| Cash & Equiv. | $89M | $532M |
CHRS vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CHRS
PRGO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | 100 | 9.4 | -90.6% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CHRS vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CHRS leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Perrigo Company plc is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CHRS
Coherus Oncology, Inc.
The Value Play
CHRS carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (1.2x vs 5.6x)
- 398.4% margin vs PRGO's -43.5%
- +86.0% vs PRGO's -51.2%
Best for: value and quality
PRGO
Perrigo Company plc
The Income Pick
PRGO is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Rev growth -2.8%, EPS growth -7.2%, 3Y rev CAGR -1.5%
- -77.7% 10Y total return vs CHRS's -90.8%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRGO | -2.8% revenue growth vs CHRS's -84.2% |
| Value | CHRS | Lower P/E (1.2x vs 5.6x) |
| Quality / Margins | CHRS | 398.4% margin vs PRGO's -43.5% |
| Stability / Safety | PRGO | Beta 1.18 vs CHRS's 2.29 |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | CHRS | +86.0% vs PRGO's -51.2% |
| Efficiency (ROA) | CHRS | 42.4% ROA vs PRGO's -19.8% |
CHRS vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
CHRS vs PRGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRGOLAGGINGCHRS
CHRSCoherus Oncology, Inc.
1leads
PRGOPerrigo Company plc
3leads
6 Total Categories
CATEGORYLEADERvs CHRSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRGO4/6
Valuation MetricsMultiples, price ratios, and targets
PRGO3/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CHRS5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
PRGO4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRGO leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 99.1x CHRS's $42M. CHRS is the more profitable business, keeping 4.0% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, PRGO holds the edge at -7.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CHRSCoherus Oncology,… | PRGOPerrigo Company p… |
|---|---|---|
| RevenueTrailing 12 months | $42M | $4.2B |
| EBITDAEarnings before interest/tax | -$184M | $58M |
| Net IncomeAfter-tax profit | $168M | -$1.8B |
| Free Cash FlowCash after capex | -$139M | $108M |
| Gross MarginGross profit ÷ Revenue | -37.3% | +34.2% |
| Operating MarginEBIT ÷ Revenue | -4.3% | -4.1% |
| Net MarginNet income ÷ Revenue | +4.0% | -43.5% |
| FCF MarginFCF ÷ Revenue | -3.3% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -76.5% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +29.5% | -56.4% |
PRGO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | CHRSCoherus Oncology,… | PRGOPerrigo Company p… |
|---|---|---|
| Market CapShares × price | $213M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $126M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | 1.23x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 5.06x | 0.38x |
| Price / BookPrice ÷ Book value/share | 3.47x | 0.55x |
| Price / FCFMarket cap ÷ FCF | — | 11.12x |
PRGO leads this category, winning 3 of 3 comparable metrics.
Profitability & Efficiency
CHRS leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
CHRS delivers a 7.9% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-51 for PRGO. CHRS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x.
| Metric | CHRSCoherus Oncology,… | PRGOPerrigo Company p… |
|---|---|---|
| ROE (TTM)Return on equity | +7.9% | -50.7% |
| ROA (TTM)Return on assets | +42.4% | -19.8% |
| ROICReturn on invested capital | — | +3.7% |
| ROCEReturn on capital employed | -127.8% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 1.35x |
| Net DebtTotal debt minus cash | -$87M | $3.4B |
| Cash & Equiv.Liquid assets | $89M | $532M |
| Total DebtShort + long-term debt | $1M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | -28.88x | -7.20x |
CHRS leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
PRGO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRGO five years ago would be worth $3,986 today (with dividends reinvested), compared to $1,229 for CHRS. Over the past 12 months, CHRS leads with a +86.0% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors PRGO at -25.2% vs CHRS's -40.0% — a key indicator of consistent wealth creation.
| Metric | CHRSCoherus Oncology,… | PRGOPerrigo Company p… |
|---|---|---|
| YTD ReturnYear-to-date | +28.5% | -13.5% |
| 1-Year ReturnPast 12 months | +86.0% | -51.2% |
| 3-Year ReturnCumulative with dividends | -78.4% | -58.1% |
| 5-Year ReturnCumulative with dividends | -87.7% | -60.1% |
| 10-Year ReturnCumulative with dividends | -90.8% | -77.7% |
| CAGR (3Y)Annualised 3-year return | -40.0% | -25.2% |
PRGO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CHRS and PRGO each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRGO is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than CHRS's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CHRS currently trades 67.3% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CHRSCoherus Oncology,… | PRGOPerrigo Company p… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.29x | 1.18x |
| 52-Week HighHighest price in past year | $2.62 | $28.44 |
| 52-Week LowLowest price in past year | $0.71 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +67.3% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 48.5 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 3.4M |
Evenly matched — CHRS and PRGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CHRS as "Buy" and PRGO as "Hold". Consensus price targets imply 242.0% upside for CHRS (target: $6) vs 70.6% for PRGO (target: $20). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | CHRSCoherus Oncology,… | PRGOPerrigo Company p… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $6.02 | $20.00 |
| # AnalystsCovering analysts | 16 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | 10 |
| Dividend / ShareAnnual DPS | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRGO leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). CHRS leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallPerrigo Company plc (PRGO)Leads 3 of 6 categories
Loading custom metrics...
CHRS vs PRGO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CHRS or PRGO a better buy right now?
For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.
8% revenue growth year-over-year, versus -84. 2% for Coherus Oncology, Inc. (CHRS). Coherus Oncology, Inc. (CHRS) offers the better valuation at 1. 2x trailing P/E, making it the more compelling value choice. Analysts rate Coherus Oncology, Inc. (CHRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CHRS or PRGO?
Over the past 5 years, Perrigo Company plc (PRGO) delivered a total return of -60.
1%, compared to -87. 7% for Coherus Oncology, Inc. (CHRS). Over 10 years, the gap is even starker: PRGO returned -77. 7% versus CHRS's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CHRS or PRGO?
By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.
18β versus Coherus Oncology, Inc. 's 2. 29β — meaning CHRS is approximately 94% more volatile than PRGO relative to the S&P 500. On balance sheet safety, Coherus Oncology, Inc. (CHRS) carries a lower debt/equity ratio of 2% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
04Which is growing faster — CHRS or PRGO?
By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.
8% versus -84. 2% for Coherus Oncology, Inc. (CHRS). On earnings-per-share growth, the picture is similar: Coherus Oncology, Inc. grew EPS 472. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CHRS or PRGO?
Coherus Oncology, Inc.
(CHRS) is the more profitable company, earning 398. 4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 398. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -429. 5% for CHRS. At the gross margin level — before operating expenses — PRGO leads at 35. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CHRS or PRGO more undervalued right now?
Analyst consensus price targets imply the most upside for CHRS: 242.
0% to $6. 02.
07Which pays a better dividend — CHRS or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. CHRS does not pay a meaningful dividend and should not be held primarily for income.
08Is CHRS or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). Coherus Oncology, Inc. (CHRS) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, CHRS: -90. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CHRS and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CHRS is a small-cap deep-value stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while CHRS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CHRS: -76.5% · PRGO: -7.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.